Literature DB >> 301010

Treatment of pneumocystis carinii pneumonia in children.

A Lipson, W C Marshall, A R Hayward.   

Abstract

Eighteen children with pneumocystis carinii pneumonia diagnosed over a period of 16 years at a children's hospital are reviewed. All had an underlying disease, either congenital immunodeficiency or a malignancy. 15 patients were treated, 10 with pentamidine isethionate alone, 2 with both pentamidine and co-trimoxazole, and 3 with co-trimoxazole alone. 12 of the treated group recovered and the 3 untreated patients died. The 3 deaths after treatment occurred in children receiving pentamidine alone, and in whom secondary factors contributed. The side effects of treatment with pentamidine were high, and included local reactions, hypoglycaemia, and uraemia. However, our results confirm that pentamidine is an effective treatment for pneumocystis carinii pneumonia in childhood. Co-trimoxazole may be an effective and relatively nontoxic alternative treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301010      PMCID: PMC1544666          DOI: 10.1136/adc.52.4.314

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

1.  PNEUMOCYSTIS CARINII PNEUMONIA AND CONGENITAL HYPOGAMMAGLOBULINAEMIA.

Authors:  W C MARSHALL; H J WESTON; M BODIAN
Journal:  Arch Dis Child       Date:  1964-02       Impact factor: 3.791

2.  PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH HYPOGAMMAGLOBULINAEMIA RESPONDING TO PENTAMIDINE.

Authors:  T S RODGERS; M H HAGGIE
Journal:  Lancet       Date:  1964-05-09       Impact factor: 79.321

3.  Pneumocystis carinii; etiologic agent of interstitial plasma cell pneumonia of premature and young infants.

Authors:  D C GAJDUSEK
Journal:  Pediatrics       Date:  1957-04       Impact factor: 7.124

4.  Pneumocystis carinii pneumonitis in children with malignancies.

Authors:  W T Hughes; R A Price; H K Kim; T P Coburn; D Grigsby; S Feldman
Journal:  J Pediatr       Date:  1973-03       Impact factor: 4.406

5.  Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features.

Authors:  P D Walzer; D P Perl; D J Krogstad; P G Rawson; M G Schultz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

6.  Pneumocystis carinii pneumonia.

Authors:  G Ivady; L Paldy; M Koltay; G Toth; Z Kovacs
Journal:  Lancet       Date:  1967-03-18       Impact factor: 79.321

7.  Pneumocystis pneumonia transmission between patients with lymphoma.

Authors:  J H Brazinsky; J E Phillips
Journal:  JAMA       Date:  1969-09-08       Impact factor: 56.272

8.  Pneumocystic carinii pneumonia in children with cancer. Diagnosis and treatment.

Authors:  H D Johnson; W W Johnson
Journal:  JAMA       Date:  1970-11-09       Impact factor: 56.272

9.  Pneumocystis carinii pneumonia treated with pyrimethamine and sulfadiazine.

Authors:  H B Kirby; B Kenamore; J C Guckian
Journal:  Ann Intern Med       Date:  1971-10       Impact factor: 25.391

10.  Protein-calorie malnutrition. A host determinant for Pneumocystis carinii infection.

Authors:  W T Hughes; R A Price; F Sisko; W S Havron; A G Kafatos; M Schonland; P M Smythe
Journal:  Am J Dis Child       Date:  1974-07
View more
  4 in total

1.  Diagnosis and treatment of Pneumocystis carinii pneumonia.

Authors: 
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

Review 2.  Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia.

Authors:  K L Goa; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

3.  Pneumocystis carinii pneumonitis: a serological study.

Authors:  V Shepherd; B Jameson; G K Knowles
Journal:  J Clin Pathol       Date:  1979-08       Impact factor: 3.411

4.  Single dose trimethoprim-sulphamethoxazole treatment of symptomatic urinary infection.

Authors:  W R Pitt; S A Dyer; J L McNee; J R Burke
Journal:  Arch Dis Child       Date:  1982-03       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.